Evaluation of Short-Term Efficacy and Long-Term Oncological Outcomes of Different Paclitaxels Plus Platinum Regimens in the Treatment of Serous Ovarian Cancer—A Real World Study
February 2021
in “
Research Square (Research Square)
”
TLDR The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.
In an observational study of 2,835 patients with serous ovarian cancer in Guangxi Province, China, from January 2009 to June 2015, different paclitaxel plus platinum chemotherapy regimens were evaluated for short-term efficacy and long-term outcomes. The study found that the Liposomal-Paclitaxel+Carboplatin (Li-Pa/Ca) regimen had an Objective Remission Rate (ORR) of 88.3% and was associated with better median Progression-Free Survival (PFS) and Overall Survival (OS) compared to Docetaxel+Carboplatin (Do/Ca) and Paclitaxel+Carboplatin (Pa/Ca), although the differences were not statistically significant. The 5-year PFS and OS rates were higher for Do/Ca compared to Li-Pa/Ca. The Pa/Ca regimen showed significantly lower PFS and OS than the other two regimens. The study concluded that Li-Pa/Ca and Do/Ca regimens offer satisfactory short-term efficacy with low adverse reactions and have advantages in improving long-term prognosis compared to Pa/Ca, providing a reference for treatment in underdeveloped areas.
